SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Biogen Inc. – ‘10-Q’ for 6/30/17 – ‘EX-10.3’

On:  Tuesday, 7/25/17, at 4:22pm ET   ·   For:  6/30/17   ·   Accession #:  875045-17-24   ·   File #:  0-19311

Previous ‘10-Q’:  ‘10-Q’ on 4/25/17 for 3/31/17   ·   Next:  ‘10-Q’ on 10/24/17 for 9/30/17   ·   Latest:  ‘10-Q’ on 4/24/24 for 3/31/24   ·   4 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 7/25/17  Biogen Inc.                       10-Q        6/30/17   92:11M

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    790K 
 2: EX-10.2     Material Contract                                   HTML     40K 
 3: EX-10.3     Material Contract                                   HTML     41K 
 4: EX-10.4     Material Contract                                   HTML     42K 
 5: EX-10.5     Material Contract                                   HTML     41K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     32K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     33K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     28K 
15: R1          Document and Entity Information                     HTML     43K 
16: R2          Condensed Consolidated Statements of Income         HTML    100K 
                (Unaudited)                                                      
17: R3          Condensed Consolidated Statements of Comprehensive  HTML     53K 
                Income (Unaudited)                                               
18: R4          Condensed Consolidated Balance Sheets (Unaudited)   HTML    119K 
19: R5          Condensed Consolidated Balance Sheets (Unaudited)   HTML     28K 
                (Parenthetical)                                                  
20: R6          Condensed Consolidated Statements of Cash Flows     HTML    100K 
                (Unaudited)                                                      
21: R7          Summary of Significant Accounting Policies          HTML     55K 
22: R8          Acquisitions                                        HTML     28K 
23: R9          Hemophilia Spin Off                                 HTML     48K 
24: R10         Reserves for Discounts and Allowances               HTML     57K 
25: R11         Inventory                                           HTML     43K 
26: R12         Intangible Assets and Goodwill                      HTML     93K 
27: R13         Fair Value Measurements                             HTML    165K 
28: R14         Financial Instruments                               HTML    141K 
29: R15         Derivative Instruments                              HTML     98K 
30: R16         Property, Plant and Equipment Property, Plant and   HTML     30K 
                Equipment                                                        
31: R17         Equity                                              HTML     51K 
32: R18         Accumulated Other Comprehensive Income (Loss)       HTML    109K 
                Accumulated Other Comprehensive Income (Loss)                    
33: R19         Earnings per Share                                  HTML     56K 
34: R20         Share-based Payments                                HTML     88K 
35: R21         Income Taxes                                        HTML     58K 
36: R22         Other Consolidated Financial Statement Detail       HTML     68K 
37: R23         Investments in Variable Interest Entities           HTML     33K 
38: R24         Collaborative and Other Relationships               HTML     48K 
39: R25         Litigation                                          HTML     45K 
40: R26         Summary of Significant Accounting Policies Summary  HTML     64K 
                of Significant Accounting Policies (Policies)                    
41: R27         Hemophilia Spin Off (Tables)                        HTML     42K 
42: R28         Reserves for Discounts and Allowances (Tables)      HTML     58K 
43: R29         Inventory (Tables)                                  HTML     43K 
44: R30         Intangible Assets and Goodwill (Tables)             HTML     79K 
45: R31         Fair Value Measurements (Tables)                    HTML    165K 
46: R32         Financial Instruments (Tables)                      HTML    146K 
47: R33         Derivative Instruments (Tables)                     HTML     91K 
48: R34         Equity (Tables)                                     HTML     43K 
49: R35         Accumulated Other Comprehensive Income (Loss)       HTML    111K 
                Accumulated Other Comprehensive Income (Loss)                    
                (Tables)                                                         
50: R36         Earnings per Share (Tables)                         HTML     56K 
51: R37         Share-Based Payments (Tables)                       HTML     86K 
52: R38         Income Taxes (Tables)                               HTML     55K 
53: R39         Other Consolidated Financial Statement Detail       HTML     67K 
                (Tables)                                                         
54: R40         Summary of Significant Accounting Policies Summary  HTML     27K 
                of Significant Accounting Policies (Details)                     
55: R41         Acquisitions (Details Textual)                      HTML     27K 
56: R42         Hemophilia Spin Off (Details)                       HTML     64K 
57: R43         Hemophilia Spin Off (Details Textual)               HTML     45K 
58: R44         Reserves for Discounts and Allowances (Details)     HTML     46K 
59: R45         Reserves for Discounts and Allowances (Details 1)   HTML     31K 
60: R46         Inventory (Details)                                 HTML     39K 
61: R47         Inventory Inventory (Details Textual)               HTML     33K 
62: R48         Intangible Assets and Goodwill (Details)            HTML    112K 
63: R49         Intangible Assets and Goodwill (Details 1)          HTML     47K 
64: R50         Fair Value Measurements (Details)                   HTML     94K 
65: R51         Fair Value Measurements (Details 1)                 HTML     47K 
66: R52         Fair Value Measurements (Details 2)                 HTML     38K 
67: R53         Fair Value Measurements (Details Textual)           HTML     45K 
68: R54         Financial Instruments (Details)                     HTML     35K 
69: R55         Financial Instruments (Details 1)                   HTML     57K 
70: R56         Financial Instruments (Details 2)                   HTML     47K 
71: R57         Financial Instruments (Details 3)                   HTML     32K 
72: R58         Financial Instruments (Details Textual)             HTML     26K 
73: R59         Financial Instruments Financial Instruments         HTML     27K 
                (Details Textual 2)                                              
74: R60         Derivative Instruments (Details)                    HTML     98K 
75: R61         Property, Plant and Equipment Property, Plant and   HTML     38K 
                Equipment (Details)                                              
76: R62         Equity (Details)                                    HTML     34K 
77: R63         Equity (Details Textual)                            HTML     49K 
78: R64         Accumulated Other Comprehensive Income (Loss)       HTML     55K 
                Accumulated Other Comprehensive Income (Loss)                    
                (Details)                                                        
79: R65         Accumulated Other Comprehensive Income (Loss)       HTML     47K 
                Accumulated Other Comprehensive Income (Loss)                    
                (Details 1)                                                      
80: R66         Earnings per Share (Details)                        HTML     49K 
81: R67         Share-Based Payments (Details)                      HTML     46K 
82: R68         Share-Based Payments (Details 1)                    HTML     53K 
83: R69         Income Taxes (Details)                              HTML     52K 
84: R70         Income Taxes (Details Textual)                      HTML     27K 
85: R71         Other Consolidated Financial Statement Detail       HTML     69K 
                (Details)                                                        
86: R72         Other Consolidated Financial Statement Detail       HTML     34K 
                Other Consolidated Financial Statement (Details                  
                Textual)                                                         
87: R73         Investments in Variable Interest Entities           HTML     30K 
                (Details)                                                        
88: R74         Collaborative and Other Relationships               HTML     74K 
                Collaborative and Other Relationships -                          
                Collaborations (Details)                                         
89: R75         Collaborative and Other Relationships               HTML     39K 
                Collaborative and Other Relationships - Equity                   
                Method Investments (Details)                                     
91: XML         IDEA XML File -- Filing Summary                      XML    164K 
90: EXCEL       IDEA Workbook of Financial Reports                  XLSX    101K 
 9: EX-101.INS  XBRL Instance -- biib-20170630                       XML   2.97M 
11: EX-101.CAL  XBRL Calculations -- biib-20170630_cal               XML    234K 
12: EX-101.DEF  XBRL Definitions -- biib-20170630_def                XML    626K 
13: EX-101.LAB  XBRL Labels -- biib-20170630_lab                     XML   1.67M 
14: EX-101.PRE  XBRL Presentations -- biib-20170630_pre              XML    976K 
10: EX-101.SCH  XBRL Schema -- biib-20170630                         XSD    174K 
92: ZIP         XBRL Zipped Folder -- 0000875045-17-000024-xbrl      Zip    253K 


‘EX-10.3’   —   Material Contract


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Exhibit  


Exhibit 10.3

MARKET STOCK UNIT AWARD AGREEMENT
GRANTED UNDER
BIOGEN INC. 2017 OMNIBUS EQUITY PLAN
1.
Grant of Market Stock Units
Pursuant to the Biogen Idec Inc. 2017 Omnibus Equity Plan (as it may be amended from time to time, the “Plan”), Biogen Inc. (the “Company”) hereby grants to you, an employee of the Company or one of its Affiliates (the “Participant”), on each of the grant dates specified on your Fidelity stock plan account (the “Grant Date”), the number of market stock units (the “Granted MSUs” or the “Award”) specified on your Fidelity stock plan account, subject to the terms and conditions of this award agreement (“Agreement”) and the Plan. No MSU shall be paid unless vested in accordance with this Agreement. The Participant’s rights to the Granted MSUs granted pursuant to this Agreement are subject to the restrictions described in this Agreement and the Plan, in addition to such other restrictions, if any, as may be imposed by law. All initially capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified in this Agreement.
2.
Vesting
A.    The Participant shall have a non-forfeitable right to a portion of the Award only upon the vesting dates specified on your Fidelity stock plan account, except as otherwise provided herein or determined by the Committee in its sole discretion. No portion of any Award shall become eligible to vest on the vesting date unless the Participant is then, and since the Grant Date has continuously been, employed by the Company or any Affiliate. If the Participant ceases to be employed by the Company and its Affiliates for any reason, any then outstanding and unvested portion of the Award shall be automatically and immediately forfeited and terminated, except as otherwise provided in this Agreement and the Plan.
B.    (i) The Award will become eligible to vest in in three equal installments on each of the first, second and third anniversaries of the Grant Date (each a “Vesting Date” and collectively, the “Vesting Period”).
(ii) On each Vesting Date, the number of MSUs that become eligible to vest on such Vesting Date will vest based upon the change in the Company’s share price between the Vesting Date and the Grant Date. The calculation of the number of Granted MSUs that will vest is specified in the Long-Term Incentive Program Overview for Executives for the year in which the Award is granted (“LTI Overview”), which is also found on your Fidelity stock plan account. In the event and to the extent that a number of the Granted MSUs then eligible to vest do not vest on the applicable Vesting Date in accordance with this Agreement and the LTI Overview, such Granted MSUs shall be immediately forfeited. In the event that the threshold is not met based on the calculation described in the LTI Overview, any Granted MSUs then eligible to vest shall not vest and shall be immediately forfeited. In the event and to the extent that the target is exceeded based on the calculation described in the LTI Overview, an additional number of Granted MSUs will vest. In no event shall the number of Granted MSUs that vest on the applicable Vesting Date exceed 200% of the Granted MSUs that became eligible to vest on such Vesting Date.
C.    Except as otherwise provided in the Plan, upon termination of the Participant’s employment with the Company and its Affiliates for any reason, any portion of the Award that is not then vested will immediately terminate, except as follows:
(1)    any portion of the Award held by the Participant immediately prior to the Participant’s termination of employment on account of death or Disability will, to the extent not vested previously, become eligible to vest as of the date of such termination of employment, and such





Granted MSUs then eligible to vest will vest in accordance with Section 2.B.(ii) with the date of the termination of employment serving as the applicable Vesting Date; and
(2)    any portion of the Award held by the Participant immediately prior to the Participant’s Retirement, to the extent not vested previously, will remain outstanding and will become eligible to vest over the remainder of the Vesting Period as set forth in Section 2.B.(i) without regard to the service requirement specified in Section 2.A., for fifty percent (50%) of the number of Granted MSUs covered by such unvested portion and for an additional ten percent (10%) of the number of Granted MSUs covered by such unvested portion for every full year of employment by the Company and its Affiliates beyond ten (10) years, up to the remaining amount of the unvested Granted MSUs, and such Granted MSUs that become eligible to vest will vest in accordance with Section 2.B.(ii). For the avoidance of doubt, Retirement means the Participant’s leaving the employment of the Company and its Affiliates after reaching age 55 with ten (10) consecutive years of service with the Company or its Affiliates, but not including pursuant to any termination For Cause or any termination for insufficient performance, as determined by the Company.
D.    Notwithstanding anything herein to the contrary, any portion of the Award held by a Participant or a Participant’s permitted transferee immediately prior to the cessation of the Participant’s employment For Cause shall terminate at the commencement of business on the date of such termination.
3.
Delivery of Award
A.    With respect to a Participant who is not eligible for Retirement, within 30 days following the date on which a Granted MSU becomes vested, the Company shall issue to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, one share of common stock of the Company (“Common Stock”) in satisfaction of each vested MSU.
B.    With respect to a Participant who is or becomes eligible for Retirement at any time during the Vesting Period, the Company shall issue to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, one share of Common Stock in satisfaction of each vested MSU (determined in accordance with Section 2 of this Agreement and Section 10 of the Plan) within 30 days of the earliest of (i) the date the Granted MSU otherwise would have vested under Sections 2.B. and 2.C. of this Agreement or (ii) the date on which a Covered Transaction that satisfies the definition of a “change in control event” under Section 409A occurs.
C.    If you are a “specified employee” (as defined in Section 409A), you will be paid on the earlier of (i) the date which is six months after you separate from service (within the meaning of Section 409A) or (ii) the date of your death or Disability. The preceding sentence will not apply to any payments that are exempt from or are not subject to the requirements of Section 409A. For the avoidance of doubt, if payments would be made under Section 3.B.(i) or Section 3.B.(ii) before the six month payment date on account of other than your separation from service, such payment will be made under Section 3.B.(i) or Section 3.B.(ii), as applicable.
4.
Cancellation and Rescission of Awards
The Committee may cancel, rescind, withhold or otherwise limit or restrict the Award prior to payment at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.





5.
No Voting, Dividend or Other Rights as a Stockholder
The Participant shall not have any rights as a stockholder with respect to any shares of Common Stock to be issued under the Award until he or she becomes the holder of such shares. Accordingly, the Award shall not be interpreted to bestow upon the Participant any equity interest or ownership in the Company or any Affiliate prior to the date on which the Company delivers to the Participant shares of Common Stock. Furthermore, the Participant is not entitled to vote any Common Stock by reason of the granting of the Award or to receive or be credited with any dividends declared and payable on any share of Common Stock underlying the Award prior to the payment date with respect to such share.
6.
Unfunded Status
The obligations of the Company and its Affiliates hereunder shall be contractual only and all such payments shall be made from the general assets of the Company and its Affiliates. The Participant shall rely solely on the unsecured promise of the Company and nothing herein shall be construed to give the Participant or any other person or persons any right, title, interest or claim in or to any specific asset, fund, reserve, account or property of any kind whatsoever owned by the Company or any Affiliate.
7.
Withholding
Awards will be subject to income tax withholding and reporting as required under local law. If statutory withholding of taxes and/or social insurance is required at the time of vesting, the Company will withhold from delivery to the Participant a number of shares of Common Stock equal in value to the statutory minimum amount required to be withheld. A similar amount of cash will be paid by the Company on behalf of the Participant to the applicable tax authorities. The number of shares to be withheld will be calculated using the closing sales price of a share of Common Stock on the applicable Vesting Date. Shares (net of the number withheld for the payment of withholding taxes, if applicable) will be delivered to the Participant’s stock plan account upon vesting in accordance with the Plan. The Company may, in its discretion, permit Participants to make alternative arrangements for payment of any such taxes and/or social insurance.
In certain cases, local law may require that an award be subject to tax earlier than the date of payment. If that occurs, the Company will notify the Participant and will deduct the required tax amount from the Participant’s pay in accordance with applicable law.
8.
Provisions of the Plan
The Award is subject to the provisions of the Plan, which are incorporated herein by reference, and in the event of any inconsistency or conflict between the provisions of this Agreement and the Plan, the provisions of the Plan shall control. A copy of the Plan as in effect on the Grant Date has been made available electronically to the Participant.
9.    No Right to Employment
The grant of the Award shall not constitute a contract of employment or confer upon the Participant any right with respect to the continuance of his/her employment by or other service with the Company or any Affiliate, nor shall it or they be construed as affecting the rights of the Company (or any Affiliate) to terminate the service of the Participant at any time or otherwise change the terms of such service, including, without limitation, the right to promote, demote or otherwise re-assign the Participant from one position to another within the Company or any Affiliate.





10.    Governing Law
The provisions of the Award and this Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware.
IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized officer.
Biogen Inc.

By:    Michel Vounatsos    
Chief Executive Officer




Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed on:7/25/174,  8-K
For Period end:6/30/17
 List all Filings 


4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/14/24  Biogen Inc.                       10-K       12/31/23  176:24M
 2/15/23  Biogen Inc.                       10-K       12/31/22  170:30M
 2/03/22  Biogen Inc.                       10-K       12/31/21  162:26M
 2/03/21  Biogen Inc.                       10-K       12/31/20  163:30M
Top
Filing Submission 0000875045-17-000024   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., May 9, 11:09:41.1pm ET